-
England captain Stokes '100 percent to bowl' on return to cricket
-
Russia scolds ally Armenia for hosting Zelensky
-
France's far-right leaders court Israel, Germany envoys ahead of vote
-
Latest evacuee from hantavirus-hit cruise lands in Europe
-
Rubio meets US pope in bid to ease tensions
-
Women linked to IS fighters return to Australia from Middle East
-
Shell profit jumps as Mideast war fuels oil prices
-
Oil sinks, Tokyo leads Asia stock surge on growing Mideast peace hopes
-
India vows to crush terror 'ecosystem', a year after Pakistan conflict
-
Circus tackles jihadist nightmares of Burkina Faso's children
-
Iran denies ship attack as Trump warns of renewed bombing, eyes deal
-
Badminton looks to future with 'evolution and innovation'
-
Troubled waters: Jakarta battles deadly, invasive suckerfish
-
Senegal's children mourn in silence when migrant parents disappear
-
EU weighs options as summer jet fuel threat looms
-
Spurs thrash Timberwolves as Knicks edge Sixers in NBA playoffs
-
Australia to force gas giants to reserve fuel for domestic use
-
AirAsia signs $19bn deal for 150 Airbus A220 jets
-
Japan fires missiles during drills, drawing China rebuke
-
Toluca rout Son's LAFC to set up all-Mexican CONCACAF final
-
Vingegaard begins bid for Giro-Tour double with Pellizzari boosting home hopes
-
Roma's Champions League return back on as Milan, Juve wobble
-
Tokyo leads Asia stock surge on growing Mideast peace hopes
-
Australia cricket great Warner to 'accept' drink-drive charge: lawyer
-
Brunson steers Knicks to 2-0 lead with tight win over Sixers
-
Rubio seeks to ease tensions with US pope
-
AI disinfo tests South Korean laws ahead of local elections
-
Australian state overturns Melbourne ban on World Cup watch party
-
Colombian ex-fisherman swaps trade for saving Caribbean coral
-
Lobito Corridor: Africa's mega-project facing delivery test
-
Africa's Lobito Corridor chief tells AFP business, not geopolitics, drives strategy
-
Trump to host Lula in test of fitful relationship
-
K-pop stars BTS draw 50,000-strong crowd in Mexico
-
Britons set to punish Starmer's Labour in local polls
-
Wars in Middle East, backyard loom over ASEAN summit
-
US court releases purported Epstein suicide note
-
Israeli court rejects flotilla activists' appeal challenging detention
-
Polaris Renewable Energy Announces Q1 2026 Results
-
How to Clear the Strait of Hormuz from the Air: UMag Solutions Launches F1Mag(R) - an Unmanned Solution for Rapid Naval Mine Detection and Anti-Submarine Warfare
-
Victim's lawyer alleges Boeing was 'negligent' in 2019 Ethiopian crash
-
Williamson named in New Zealand squad for Ireland, England Tests
-
PSG add muscle to magic as another Champions League final beckons
-
Tigers' pitcher Valdez suspended for hitting opponent
-
Trump says Iran deal 'very possible' but threatens strikes if talks fail
-
Musk's SpaceX strikes data center deal with Anthropic
-
Bayern lament lack of 'killer' instinct after PSG elimination
-
Virus-hit cruise ship heads for Spain as evacuees land in Europe
-
Holders PSG edge Bayern Munich to reach Champions League final
-
Russia warns diplomats in Kyiv to evacuate in case of strike
-
Hantavirus ship passenger: 'They didn't take it seriously enough'
Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
D.Schneider--BTB